New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For AAPL;JPM;RDSA;NVS;BKS;WDC;GD;VIA;VIAB;BLK;MPC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | all recent news | >>
January 23, 2015
16:01 EDTAAPLOptions Update; January 23, 2015
iPath S&P 500 VIX Short-Term Futures up 80c to 32.10. Option volume leaders: AAPL TSLA TWTR AMZN FB FXCM X GDP PBR according to Track Data.
15:17 EDTAAPLApple volatility at upper end of five-year range into Q1
Apple January weekly call option implied volatility is at 51, February is at 33, March is at 32; compared to its 26-week average of 26 according to Track Data, suggesting larger price movement into the expected release of Q1 results on January 27.
12:33 EDTNVSOn The Fly: Midday Wrap
Stocks on Wall Street were mixed at midday, with the Nasdaq leading and the Dow lagging. The futures dipped this morning after UPS (UPS) pre-announced that its quarterly earnings would miss Street estimates. The earnings miss dragged other transportation names lower. ECONOMIC EVENTS: In the U.S., Markit's preliminary January manufacturing PMI fell to 53.7 from 53.9 previously, versus expectations for a reading of 54.0. Existing home sales rebounded 2.4% to a 5.04M rate in December, which was below the consensus forecast for a 3% increase. The leading indicators rose 0.5% to 121.1 in December, topping expectations for a rise of 0.4%. COMPANY NEWS: Shares of UPS plunged over 9% after the shipping giant warned that its Q4 adjusted EPS is now expected to be $1.25, below the consensus forecast of $1.47. "UPS invested heavily to ensure we would provide excellent service during peak when deliveries more than double. Though customers enjoyed high quality service, it came at a cost to UPS. Going forward, we will reduce operating costs and implement new pricing strategies during peak season,” said CEO David Abney. Subsequently, its peer, FedEx (FDX), reaffirmed its FY15 EPS forecast of $8.50-$9.00. The outlook compares to a consensus forecast of $8.97. FedEx shares, which were briefly halted for the announcement, are down 2% afterward... Shares of McDonald’s (MCD) slid about 1% near noon after its earnings miss, though the world’s largest restaurant chain's same-store sales declined less than analysts expected. Same-store sales in the company's fiscal fourth quarter declined 0.9%, versus the Consensus Metrix analysts' estimate for a 1.5% drop. Of note, McDonald’s U.S. same-store sales had their first monthly gain in more than a year in December, having risen 0.4%. MAJOR MOVERS: Among the notable gainers was Starbucks (SBUX), which rose 6.5% and had several research firms issue upbeat notes after the company reported in-line results last night. At least three firms responded to the report by raising their price targets on the shares. Also higher was Array BioPharma (ARRY), which jumped 38% after announcing that it has reached a definitive agreement with Novartis (NVS) to acquire worldwide rights to encorafenib, a BRAF inhibitor currently in Phase 3 development. Among the noteworthy losers was Avon Products (AVP), which dropped 11% after Wells Fargo downgraded the stock to Market Perform from Outperform after shares rallied yesterday over 14% following a report that the company has held talks with TPG Capital about a possible deal. Wells says it leveraged buyout math suggests a takeout of the entire company is unlikely. Also lower was DreamWorks Animation (DWA), which fell 9% after announcing a new strategic plan that will see it cut its feature production from three films per year down to two and cut about 500 jobs. INDEXES: Near midday, the Dow was down 42.58, or 0.24%, to 17,771.40, the Nasdaq was up 9.68, or 0.2%, to 4,760.08, and the S&P 500 was down 3.40, or 0.16%, to 2,059.75.
10:44 EDTAAPLPandora rallies after analyst releases upbeat survey results
Subscribe for More Information
09:36 EDTAAPLActive equity options trading
Subscribe for More Information
08:52 EDTNVSArray BioPharma to hold a conference call
Subscribe for More Information
08:10 EDTNVSArray agrees to acquire rights to encorafenib
Array BioPharma (ARRY) announced that it has reached a definitive agreement with Novartis (NVS) to acquire worldwide rights to encorafenib, a BRAF inhibitor currently in Phase 3 development. This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline (GSK) on April 22, 2014, which are expected to close in the first half of 2015, and the agreement remains subject to the receipt of regulatory approvals. Array previously announced a definitive agreement with Novartis to regain global rights to the Phase 3 MEK inhibitor binimetinib, the material terms of which remain in place following this agreement. In order to address competition concerns raised by the European Commission, Array has agreed to obtain an experienced partner for global development and European commercialization of both binimetinib and encorafenib. The European Commission is expected to issue a decision regarding the Novartis-GSK transaction on January 28, 2015. Upon satisfaction of all conditions and closing of the deal, Array will acquire global rights to encorafenib. Other than a de minimis payment due to Novartis from Array, there are no milestone payments or royalties payable under this agreement by either party. Novartis has agreed to provide transitional regulatory, clinical development and manufacturing services as specified below and will assign or license to Array all patent and other intellectual property rights Novartis owns to the extent relating to encorafenib. As part of the transaction, Array has agreed to obtain an experienced partner for global development and European commercialization of both binimetinib and encorafenib. If Array is unable to find a suitable partner in the prescribed time period, a trustee would have the right to sell such European rights. Novartis will conduct and fund the COLUMBUS trial through the earlier of June 30, 2016 or completion of last patient first visit. At that time, Array will assume responsibility for the trial, while Novartis will reimburse Array for out-of-pocket costs along with 50% of Array's full time equivalent costs in connection with completing the COLUMBUS trial. Novartis is responsible for conducting all other encorafenib trials until their completion or transfer to Array for a defined transition period. For all trials transferred to Array, Novartis will reimburse Array for out-of-pocket costs and 50% of Array's FTE costs in connection with completing the trials. Novartis will supply encorafenib for clinical and commercial use for up to 30 months after closing and will also assist Array in the technology and manufacturing transfer of encorafenib. Novartis will also provide Array continued access to several Novartis pipeline compounds for use in currently ongoing combination studies, and possible future studies, including Phase 3 trials, with encorafenib. The effectiveness of the agreement is subject to the receipt of regulatory approvals and to the consummation of the Novartis-GSK transaction. In addition, Array agreed to undertake to obtain certain third party consents or waivers necessary for Array to consummate the transactions under the Novartis Agreement.
07:36 EDTNVSIncyte earns $25M milestone payment from Novartis for Jakavi
Subscribe for More Information
07:28 EDTAAPLDeutsche sees limited near-term catalysts for Apple shares
Deutsche Bank raised its Q1 estimates for Apple to reflect strong iPhones sales and now believes 67M phones shipped in the quarter. It notes that expectations are likely closer to 70M. Deutsche sees limited near-term catalysts for the stock, however, with iPhone sales peaking in Q1 and Apple Watch not expected to ship until the end of Q2. It keeps a Hold rating on Apple shares with a $102 price target.
07:25 EDTNVSNovartis drug Jakavi recommended by CHMP for EU approval
Subscribe for More Information
07:23 EDTJPMBass does not expect large U.S. banks to break up
Publicly traded companies in the space include Bank of America (BAC), Citi (C), JPMorgan (JPM), and Wells Fargo (WFC). Kyle Bass of Hayman Capital continues speaking on CNBC.
06:42 EDTJPMU.S. banks preparing for prolonged low bond yields, Reuters says
Subscribe for More Information
06:22 EDTAAPLApple sees strong growth in Asian smartphone sales, CNBC says
Apple (AAPL) captured 33% of South Korea's smartphone market share in November, reports CNBC, citing Counterpoint Research. South Korean Samsung's (SSNLF) market share fell from 60% six months earlier to 46%. Apple also captured over 50% market share in Japan and saw a rise to 12% in China behind Lenovo (LNVGY) and Xiaomi. Reference Link
06:12 EDTAAPLFord announces opening of Palo Alto engineering center
Ford (F) yesterday opened the Research and Innovation Center Palo Alto, growing its global research team and accelerating the company’s innovation in connectivity, mobility, autonomous vehicles, customer experience and big data. The all-new Research and Innovation Center Palo Alto joins Ford’s global network of research and innovation centers, including its location in Dearborn, Michigan, which focuses on advanced electronics, human-machine interface, materials science, big data and analytics; and Aachen, Germany, which focuses on next-generation powertrain research, driver-assist technologies and active safety systems. With the new facility, Ford expects to have one of the largest automotive manufacturer research centers in Silicon Valley by the end of the year, with 125 researchers, engineers and scientists. Located in Stanford Research Park, the facility also expands Ford’s physical footprint – with further expansion planned in the near future. Ford opened its first Silicon Valley office in 2012. Leading the new research center is Dragos Maciuca, an engineer who joins Ford from Apple (AAPL) with a background in consumer electronics, semiconductor manufacturing, aerospace and automotive. While Ford’s research and development in autonomous vehicles is a global effort, including ongoing work with University of Michigan and Massachusetts Institute of Technology, the Palo Alto team will expand collaboration with Stanford University that kicked off in 2013. For this next phase of research, Ford is contributing a Fusion Autonomous Research Vehicle to the Stanford engineering program to begin testing the path planning-and-prediction algorithms researchers have developed over the past year. Ford is integrating with the Nest application programming interface, targeting home energy and emergency system management while on the road through a series of research experiments.
05:55 EDTAAPLApple ranks top smartphone vendor in Taiwan for December, DigiTimes reports
Apple has ranked as the top smartphone vendor in the Taiwan market in December in both sales and volume, reports DigiTimes. According to data compiled by local retail channels, Apple took a 25.9% share in sales volume and 53.2% in sales value due to its success in iPhone 6 sales. Reference Link
05:52 EDTAAPLGartner: Samsung, Apple remain top semiconductor buyers in 2014, Digitimes says
Subscribe for More Information
January 22, 2015
17:18 EDTAAPLJ. Crew CEO Mickey Drexler to retire from Apple board
Subscribe for More Information
16:22 EDTJPMJPMorgan CEO Dimon gets stock-based compensation of 198.5K shares for 2014
Subscribe for More Information
16:00 EDTAAPLOptions Update; January 22, 2015
iPath S&P 500 VIX Short-Term Futures down 2.13 to 31.32 Option volume leaders: AAPL TSLA TWTR AMZN FB FXCM AVP BAC according to Track Data.
14:36 EDTJPMCFPB fines Wells Fargo, JPMorgan for kickback scheme
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use